Successful Omalizumab Therapy for Bullous Pemphigoid Despite Transient Reaction
Successful Omalizumab Therapy for Bullous Pemphigoid Despite Transient Reaction
J Drugs Dermatol. 2019 Sep 01;18(9):947-949
Authors: Ewy S, Pham H, Quan K, Su B, Tachdjian R
Abstract
Bullous pemphigoid (BP) is a rare blistering skin disease that is commonly treated with corticosteroids and immunosuppressive agents. Here, we present a 74-year-old woman with severe BP following a leg fracture who was successfully treated with omalizumab. We started her on a regimen of omalizumab 300 mg subcutaneously every 4 weeks, and within a week she reported significantly decreased pain and faster healing time of lesions. Incidentally, bilateral erythematous, non-blistering dermatitis developed 5 centimeters distal to the injection sites within a week of her first injection and resolved spontaneously in 2 days. She continues to tolerate the omalizumab injections well after 28 months of treatment and has not developed the injection site dermatitis since the first administration. Omalizumab appears to be a promising treatment modality for BP even when associated with transient injection site reactions, but further studies investigating the mechanisms by which omalizumab reduces bullae in BP are needed.
J Drugs Dermatol. 2019;18(9):947-949.
PMID: 31524994 [PubMed - in process]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Pain | Pemphigoid | Skin | Study | Xolair